References
1.
Remuzzi G, Ruggenenti P, Bertani T: Thrombotic microangiopathy; in Tisher CC, Brunner BM (eds): Renal Pathology with Clinical and Functional Correlations, ed 2. Philadelphia, Lippincott, 1994, pp 1154–1184.
2.
Harell RM, Sibley R, Vogelzang NJ: Renal vascular lesions after chemotherapy with vinblastine, bleomycin and cisplatin. Am J Med 1982;73: 429–432.
3.
Dang-Vu AP, Olsen EA, Vollmer RT, Greenberg ML, Hershfield MS: Treatment of cutaneous T cell lymphoma with 2′-deoxycoformycin (pentostatin). J Am Acad Dermatol 1988;19:692–698.
4.
Cummings FJ, Kim K, Neiman RS, Comis RL, Oken MM, Weitzman AS, Mann RB, O’Connell MJ: Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991;9:565–571.
5.
Grever MR, Bisaccia E, Scarborough DA, Metz EN, Neidhart JA: An investigation of 2′-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1993;61:279–282.
6.
Tallman MS, Hakimian D: Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 1995;86:2463–2474.
7.
Greiner D, Olsen EA, Petroni G: Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1997;36: 950–955.
8.
Foss FM, Ihde DC, Breneman DI, Phelps RM, Rischmann AB, Schechter GP, Linnoila I, Breneman JC, Cotelingam JD, Ghosh BC, Steinberg SM, Lynch JW, Phares JC, Stocker JL, Bastian A, Sausville EA: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides and Sézary syndrome. J Clin Oncol 1992;19: 1907–1913.
9.
Harell RM, Sibley R, Vogelzang NJ: Renal vascular lesions after chemotherapy with vinblastine, bleomycin and cisplatin. Am J Med 1982;73:429– 432.
10.
Jackson AM, Rose BD, Graff LG, Schwartz JH, Strauss GM, Yang JP, Rudnick MR, Elfenbein IB, Narins RG: Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann Intern Med 1984; 101:41–44.
11.
Harris DCH, Lawrence S, Bradstock KF, Carter JJ, Jones WG: Intraglomerular thrombosis with deoxycoformycin-reversible acute renal failure. Clin Nephrol 1984;21:194–196.
12.
Sakai C, Takagi T, Waikatsuki S, Matsuzaki O: Hemolytic-uremic syndrome due to deoxycoformycin: A report of the second case. Intern Med 1995;34:593–596.
13.
Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, Arbus M, Woolley PV, Chiazze L, Schein PS, Neefe JR: Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry. J Clin Oncol 1989;7:781–789.
14.
Quesada JR, Talpaz M, Rio AS: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986;4:234–243.
15.
Baron S, Tyring SK, Fleischmann R, Coppenhaver DH, Niesel DW, Klimpel GR, Stanton J, Hughes TK: The interferons: Mechanisms of action and clinical applications. JAMA 1991;266:1375–1383.
16.
Spencer CM, Goa KL: Amifostine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 1995;50:1001–1031.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
